不同乳腺组织中肿瘤相关巨噬细胞与CXCL12表达的相关性

Correlation Between Tumor Associated Macrophages and CXCL12 Expression in Different Breast Tissues

目的探讨CXCL12表达和肿瘤相关巨噬细胞(TAMs)浸润在乳腺癌转移灶、乳腺癌原发灶及乳腺癌癌前病变中的相关性及其临床意义。方法应用免疫组织化学法检测127例乳腺癌、71例乳腺癌转移灶、100例乳腺非典型导管增生、40例乳腺腺病组织中CXCL12的表达和TAMs的浸润情况。结果 CXCL12与TAMs在各组表达的阳性率分别为:乳腺腺病组为12.5%和7.5%,乳腺非典型导管增生组为39%和18%,乳腺癌原发灶组为63.8%和57.5%,乳腺癌转移灶组为78.9%和80.3%,CXCL12与TAMs在各组间表达水平的差异有统计学意义(P<0.001),乳腺癌CXCL12与TAMs的表达分别与患者淋巴结转移、远处转移及临床TNM分期有关(P<0.05),乳腺癌原发灶、乳腺癌转移灶TAMs浸润与CXCL12表达分别呈正相关(P<0.001)。结论 CXCL12与TAMs可能在乳腺癌的发生发展中发挥重要的协同作用,两者联合检测可作为乳腺癌患者淋巴结转移和远处转移的预测指标。

Objective To investigate the relationship between CXC chemokine ligand 12（CXCL12） expression and tumor associated macrophages（TAMs） in primary breast cancer, metastatic breast cancer, precancerous lesions of breast, and related clinical significance. Methods The expression of CXCL12 and the infiltration of TAMs were evaluated by Max Vision immunohistochemistry staining in 127 cases of primary breast cancer, 71 cases of metastatic breast cancer,100 cases of atypical ductal hyperplasia（ADH） and 40 cases of adenosis tissues. Results The positive rates of CXCL12 and TAMs expression were 12.5% and 7.5% in adenosis tissues, 39% and 18% in ADH tissues, 63.8% and 57.5% in primary breast cancer tissues, 78.9% and 80.3% in metastatic breast cancer tissues, respectively. There were significant differences in the expression of CXCL12 and TAMs between breast cancer and precancerous lesions of breast（P〈0.001）, and between primary breast cancer and metastatic breast cancer（P〈0.05）. There were significantly positive correlation between the expression of CXCL12 and lymph node metastasis, distant metastasis, TNM stage（P〈0.05）, and between the infiltration of TAMs and lymph node metastasis, distant metastasis, TNM stage（P〈0.05）. The expression of CXCL12 had positive correlation with TAMs in breast cancer and metastatic breast cancer（both P〈0.001）. Conclusion CXCL12 and TAMs play an important role in the occurrence and progression of breast cancer, and their joint detection may be the new prognostic marker for lymph node metastasis and distant metastasis from breast cancer.